Roche and Accenture Collaborate to Enhance Digital Healthcare for Cancer Patients

BASEL, Switzerland, Dec. 22, 2017 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced a collaborative services agreement with Accenture. Under the terms of this exclusive multi-year agreement, Accenture will provide digital data integration services to Roche's NAVIFY Tumor Board solution.

A tumour board is a meeting in which multi-disciplinary healthcare teams review and discuss individual cancer patient cases and available treatment options. The NAVIFY Tumor Board solution streamlines and standardises the tumour board workflow process by aggregating relevant patient data from disparate IT systems into a software solution that fosters efficient team collaboration, reduces errors, and gives the care team more time to evaluate individual patient cases.

The data integration capabilities Accenture provides will allow Roche to integrate patient data between hospitals and the NAVIFY Tumor Board solution to support clinicians in arriving at the best possible treatment decisions for their patients. The NAVIFY Tumor Board solution is built on a secure cloud platform.

"Our collaboration with Accenture is another exciting step forward in providing personalised healthcare solutions to patients," said Tim M. Jaeger, Global Head of Diagnostics Information Solutions for Roche. "Tumour board coordination is labor intensive and time consuming for healthcare providers. Accenture's global scale, deep digital expertise, and innovation capabilities in the healthcare and life sciences industries allows Roche to continue our focus on delivering workflow and decision support solutions to customers and improving patient outcomes." 

Koen Deryckere, who leads Accenture's Products practice in Europe, said: "With Roche, we continue to provide meaningful impact on patients' lives by combining new science with leading-edge technology to revolutionise patient care. By providing data integration services to the NAVIFY Tumor Board solution, we aim to ensure that all available data is used to accelerate and optimize treatment decisions for cancer patients."

As shared in an October 2017 announcement, the NAVIFY Tumor Board solution fundamentally changes the way tumour board meetings are organised and conducted with the goal of fostering collaboration on patient treatment decisions. It is currently available in the US, UK, Germany, Spain, Sweden, Switzerland, and the Netherlands.

SOURCE Roche